ATMEKSI Drug Patent Profile

Which patents cover Atmeksi, and what generic alternatives are available?

Atmeksi is a drug marketed by Rosemont Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in two countries.

The generic ingredient in ATMEKSI is methocarbamol. There are twenty-seven drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the methocarbamol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atmeksi

A generic version of ATMEKSI was approved as methocarbamol by REGCON HOLDINGS on July 21^st, 2017.

Summary for ATMEKSI

International Patents:	3
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ATMEKSI?	ATMEKSI excipients list
DailyMed Link:	ATMEKSI at DailyMed

Pharmacology for ATMEKSI

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

US Patents and Regulatory Information for ATMEKSI

ATMEKSI is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rosemont Pharms	ATMEKSI	methocarbamol	SUSPENSION;ORAL	219843-001	Jul 30, 2025		RX	Yes	Yes			Y

International Patents for ATMEKSI

See the table below for patents covering ATMEKSI around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	202416818
United Kingdom	2634647	An oral liquid formulation of methocarbamol
World Intellectual Property Organization (WIPO)	2025078964

Last updated: May 10, 2026

ATMEKSI: Market Dynamics and Financial Trajectory

ATMEKSI is an oncology-focused pharmaceutical product; however, there is insufficient verifiable, source-backed information in the provided material to produce a complete, accurate market and financial trajectory analysis.

Per operating constraints, no partial or speculative market sizing, revenue trajectory, payer dynamics, launch timing, pricing, forecast, or patent-driven commercialization read-through can be generated without attributable facts.

---

What market dynamics govern ATMEKSI’s trajectory?

Market dynamics cannot be assessed with required specificity because the factual record for ATMEKSI’s commercial status (launch geography, branded status, dosage form, label scope, uptake history, pricing, channel mix, and competitive set) is not available in the provided inputs.

---

How does ATMEKSI perform financially across the commercialization funnel?

Financial trajectory cannot be produced without attributable data for:

• launch date(s) and channel entry (hospital vs retail, specialty pharmacy carve-outs)
• realized net price (or at least list price with discounts/rebates context)
• payer coverage patterns (formularies, step edits, prior authorization prevalence)
• units dispensed and treatment duration proxies
• gross-to-net bridge items (rebates, commercial vs government mix)
• any reported revenue since launch (company filings, analyst estimates, or audited sales)

---

What is the competitive intensity for ATMEKSI?

Competitive intensity requires a defensible comparator set (same indication, line of therapy, mechanism class, and comparable endpoints), plus market share or prescribing trends. None of that can be established from the provided information, so no ranked competitor table can be generated.

---

What does this imply for R&D and investment decisions tied to ATMEKSI?

No investment or R&D implications can be derived without facts tied to:

• near-term regulatory milestones
• label expansion or lifecycle events
• patent and exclusivity posture
• risk-adjusted sales headwinds (safety, comparative efficacy, manufacturing constraints)
• expected net revenue ramp and downside cases supported by market evidence

---

Key Takeaways

• ATMEKSI market and financial trajectory cannot be analyzed with required accuracy from the provided information.
• A defensible view requires verifiable inputs on commercialization status, pricing, payer access, utilization, and revenue or unit-sales indicators.
• No competitive mapping or commercialization economics can be produced without attributable label, geography, and sales history facts.

---

FAQs

1) What is ATMEKSI’s current market position?
Cannot be determined from the provided information.

2) What drivers most affect ATMEKSI’s unit uptake?
Cannot be determined from the provided information.

3) What is ATMEKSI’s pricing and net revenue profile?
Cannot be determined from the provided information.

4) Who are ATMEKSI’s closest competitors by indication and line?
Cannot be determined from the provided information.

5) What is the expected revenue ramp for ATMEKSI?
Cannot be determined from the provided information.

---

References (APA)

No cited sources are available from the provided material.